Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q2 FY2024 Earnings Presentation
16 slides from Little Green Pharma's earnings presentation, Feb 8, 2024
Slide 1: Investor Webinar Invitation
ASX ANNOUNCEMENT ASX ANNOUNCEMENT 8 FEBRUARY 2024 Investor Webinar Invitation For personal use only • Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to is pleased to invite shareholders to attend an investor webinar presentation to be held at 11am AWST / 2pm AEDT today, Thursd
Slide 2: Contact details and About Little Green Pharma
For further information please contact: Alistair Warren Paul Long David Tasker / Colin Jacoby Company Secretary Chief Executive Officer Chapter One Advisors Little Green Pharma Little Green Pharma E: dtasker@chapteroneadvisors.com.au E: a.warren@lgp.global E: p.long@lgp.global / cjacoby@chapteronead
Slide 3: December 2023 Quarterly & Appendix 4C
December 2023 Quarterly & Appendix 4C For personal use only ASX:LGP Investor presentation February 2024 The most trusted medicinal cannabis brand Little Green Pharma Quarterly Activities Report and Appendix 4C
Slide 4: Disclaimer
Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation
Slide 5: Agenda
SECTION ONE Agenda For personal use only Financial performance • Revenue and cash receipts • $5.0 million R&D rebate • Net tangible assets • Net cashflows from operations New products • Launch of CherryCo brand Updates • France • Germany • United States • Reset 3
Slide 6: Revenue & cash receipts
FINANCIAL HIGHLIGHTS Revenue & cash receipts For personal use only DEC 2023 QUARTER REVENUE1 YEAR-TO-DATE REVENUE $5.4M $18.1M Quarterly revenue & cash receipts (000’s) 13% on previous quarter 25% on comparative period 8,000 6,027 6,605 DEC 2023 QUARTER CASH YEAR-TO-DATE CASH 7,000 RECEIPTS RECEIPTS
Slide 7: $5 million R&D rebate
FINANCIAL HIGHLIGHTS $5 million R&D rebate For personal use only • On 31 January 2024 the Company received its • The R&D rebate reflects the significant expenditure LGP has invested in its multi-faceted R&D program in FY2023, including: $5.0 million R&D rebate • developing one of the largest genetic
Slide 8: Net tangible assets
FINANCIAL HIGHLIGHTS Net tangible assets For personal use only • Net tangible assets continue to be significantly above the Enterprise value, net tangible assets, Company’s enterprise value cash & long-term debt (000’s) • Company’s asset base includes its Danish Facility, the largest GMP medicinal c
Slide 9: Net cashflows from operations
FINANCIAL HIGHLIGHTS Net cashflows from operations For personal use only • Product manufacturing and operating costs down 20% compared to previous quarter in part due to lower sales and therefore distribution costs • Cash receipts were down due to lower sales compounded by late collection of $1.0 mi
Slide 10: Launch of CherryCo
NEW PRODUCTS Launch of CherryCo For personal use only • CherryCo brand launched in late December 2023 • Flower sales represent over 75% of the Australian market • With CherryCo, LGP now has second largest flower portfolio in Australia • LGP in strong position to take advantage of market any future r
Slide 11: Update on France
INTERNATIONAL UPDATES Update on France For personal use only France represents one of the largest potential medicinal cannabis markets in Europe LGP has significant first-mover opportunity as the largest of only three primary suppliers to a government-backed Pilot study December 2023 marked a decisi
Slide 12: Update on Germany
INTERNATIONAL UPDATES Update on Germany For personal use only Removal of cannabis from Narcotics Act would significantly Germany’s ruling ‘Traffic Light’ coalition has resolved internal improve market accessibility through the following changes: disagreements over planned cannabis legalization bill,
Slide 13: Update on the United States
HIGHLIGHTS INTERNATIONAL UPDATES Update on the United States For personal use only • Since listing, LGP’s share price has essentially mirrored the share prices of the • In early January 2024, the HHS recommended to the North American cannabis companies as can be seen by the MJ ETF (“US ETF to DEA th
Slide 14: Reset Mind Sciences
RESET MIND SCIENCES Production For personal use only Cultivation of psilocybin mushrooms successfully commenced in 2023 at a specialised mushroom cultivation facility co-located with LGP’s South West facility. Current harvest used for chemical / physical analysis, extraction method testing and inhou
Slide 15: Corporate Overview
Corporate Overview Capital Structure Shareholder Structure For personal use only Current Share Price1 $0.14 Shares Outstanding1 ~300 million 22% Options and Performance Rights on Issue2 ~40.8 million 29% Market Capitalisation (undiluted) ~$42 million Cash Reserves (31 December 2023) $3.6 million Lon
Slide 16: Thank you
For personal use only Thank you 14
Little Green Pharma — Q2 FY2024 Earnings Presentation on 6ix